Skip to content
Biodatica
Start free

Plus Therapeutics

Chicago, Illinois

OncologyantibodyPhase IIListed · PSTV

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

2mo agoTrial registeredMay 6, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Momentum 76 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Mar 1, 2026

    Brain Tumor · NOT_YET_RECRUITING · sponsor: The University of Texas Health Science Center at San Antonio · Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

    ClinicalTrials.gov · NCT07470606 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Dec 12, 2024

    Glioma · RECRUITING · sponsor: Plus Therapeutics · Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

    ClinicalTrials.gov · NCT05460507 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 6, 2021

    Leptomeningeal Metastasis · ACTIVE_NOT_RECRUITING · sponsor: Plus Therapeutics · Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

    ClinicalTrials.gov · NCT05034497 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jun 8, 2021

    Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8 · ACTIVE_NOT_RECRUITING · sponsor: SWOG Cancer Research Network · Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

    ClinicalTrials.gov · NCT04647916 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Jun 3, 2015

    Glioma · RECRUITING · sponsor: Plus Therapeutics · Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

    ClinicalTrials.gov · NCT01906385 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources